Trials
1 active
1 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “EP0062 is an orally administered investigational selective androgen receptor modulator (SARM)”In the company’s words, NCT05573126 on ClinicalTrials.gov
- Tested for
- Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
- Main trialPhase 1/2
- “The aim of this study is to identify the optimal dose for EP0062 as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients with Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer”In the company’s words, NCT05573126 on ClinicalTrials.gov
Other drugs for Hormone Receptor-positive Breast Cancer
- D-0502InventisBio Co., Ltd · Phase 3
- ElacestrantStemline Therapeutics, Inc. · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- SPH4336Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
Coming up1
- Feb 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Feb 2028 | Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026